JENNIFER LEIGH MCQUADE to Disease-Free Survival
This is a "connection" page, showing publications JENNIFER LEIGH MCQUADE has written about Disease-Free Survival.
Connection Strength
0.074
-
Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression. Gynecol Oncol. 2022 Dec; 167(3):483-489.
Score: 0.023
-
Long-term survival among 5-year survivors of adolescent and young adult cancer. Cancer. 2020 08 15; 126(16):3708-3718.
Score: 0.019
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.016
-
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
Score: 0.015